scholarly journals PND109 PATIENT PERSPECTIVES ON THE IMPACT OF CERVICAL DYSTONIA (CD) AND BOTULINUM NEUROTOXIN TYPE A (BONT-A) TREATMENT ON WORK

2020 ◽  
Vol 23 ◽  
pp. S280
Author(s):  
C. Comella ◽  
J. Ferreira ◽  
M. Azoulai ◽  
E. Pain ◽  
S. Om
Keyword(s):  
Cervical Dystonia ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Patient Perspectives ◽  
Botulinum Neurotoxin Type A ◽  
The Impact

scholarly journals Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia

2020 ◽  
Author(s):  
Cynthia Comella ◽  
Joaquim J. Ferreira ◽  
Emilie Pain ◽  
Marion Azoulai ◽  
Savary Om
Keyword(s):  
Quality Of Life ◽  
Cervical Dystonia ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Peak Effect ◽  
Botulinum Neurotoxin Type A ◽  
The Mean ◽  
The Impact ◽  
Therapeutic Profile

Abstract Background Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals. We explored patient perceptions of the impact of CD and the waning of BoNT-A therapeutic effects. Methods An internet-based survey was conducted through Carenity, a global online patient community, from May to September 2019. Eligible respondents were adults with CD who had ≥ 2 previous BoNT-A injections. Results 209 respondents (81% females; mean age of 49.7 years) met the screening criteria. The mean BoNT-A injection frequency was 3.9 injections/year. The mean reported onset of BoNT-A therapeutic effect was 11.7 days and the time to peak effect was 4.5 weeks. Symptom re-emergence between injections was common (88%); the time from injection to symptom re-emergence was 73.6 days (~ 10.5 weeks). Treatment was not reported to completely abolish symptoms, even at peak effect. However, symptom severity was rated (0 = no symptoms; 10 = very strong symptoms) as lowest at the peak of treatment effects (mean scores ~ 3/10), increasing as the effects of treatment start waning (~ 5.5/10) and was strongest one day before the next session (~ 7–8/10). The impact of CD on quality of life followed the same ‘rollercoaster’ pattern. Conclusions This survey highlights the burden of CD symptoms, even in patients undergoing regular treatment. Symptom re-emergence is common and has significant impact on daily activities and quality of life. Greater awareness of the therapeutic profile of BoNT-A treatment should lead to better informed therapeutic discussions and planning.

scholarly journals Correction to: Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia

2020 ◽  
Author(s):  
Cynthia Comella ◽  
Joaquim J. Ferreira ◽  
Emilie Pain ◽  
Marion Azoulai ◽  
Savary Om
Keyword(s):  
Open Access ◽  
Cervical Dystonia ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Patient Perspectives ◽  
Internet Portal ◽  
Creative Commons ◽  
Botulinum Neurotoxin Type A ◽  
Therapeutic Profile

The article Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia, written by Cynthia Comella, Joaquim J. Ferreira, Emilie Pain, Marion Azoulai and Savary Om, was originally published electronically on the publisher’s internet portal on 16 September 2020 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 25 September 2020 to © The Authors 2020 and this article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

scholarly journals Long-term response in clinical practice to the application of botulinum neurotoxin type A in patients with cervical dystonia

2021 ◽  
Vol 21 (91) ◽  
Author(s):  
Minerva López-Ruiz ◽  
Sandra Quiñones-Aguilar ◽  
Juan F. Gómez Hernández ◽  
Jorge Hernández-Franco ◽  
Mayela de J. Rodríguez-Violante ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Cervical Dystonia ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Botulinum Neurotoxin Type A ◽  
Term Response

Poster 131 IncobotulinumtoxinA (XEOMIN; botulinum neurotoxin type A, free from accessory proteins): Flexibility of Dosing and Injection Intervals in Cervical Dystonia

PM&R ◽  
2011 ◽  
Vol 3 ◽  
pp. S215-S215
Author(s):  
Virgilio Gerald H. Evidente ◽  
Allison Brashear ◽  
Cynthia Comella ◽  
Hubert H. Fernandez ◽  
Susanne Grafe ◽  
...  
Keyword(s):  
Cervical Dystonia ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Accessory Proteins ◽  
Botulinum Neurotoxin Type A

Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients

Immunobiology ◽  
2016 ◽  
Vol 221 (4) ◽  
pp. 568-576 ◽  
Author(s):  
Minako Oshima ◽  
Philip Deitiker ◽  
Joseph Jankovic ◽  
K. Roger Aoki ◽  
M. Zouhair Atassi
Keyword(s):  
T Cells ◽  
Heavy Chain ◽  
Cervical Dystonia ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Botulinum Neurotoxin Type A ◽  
Terminal Domain

scholarly journals Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients’ Characteristics

2021 ◽  
Vol 18 (16) ◽  
pp. 8783
Author(s):  
Marta Tarazona-Motes ◽  
Monica Albaladejo-Belmonte ◽  
Francisco J. Nohales-Alfonso ◽  
Maria De-Arriba ◽  
Javier Garcia-Casado ◽  
...  
Keyword(s):  
Clinical Improvement ◽  
Pelvic Pain ◽  
Botulinum Neurotoxin ◽  
Protective Factor ◽  
Pelvic Floor Muscle ◽  
Clinical Status ◽  
Type A ◽  
Semg Signal ◽  
Botulinum Neurotoxin Type A ◽  
The Impact

The treatment of chronic pelvic pain (CPP) with botulinum neurotoxin type A (BoNT/A) has increased lately, but more studies assessing its effect are needed. This study aimed to evaluate the evolution of patients after BoNT/A infiltration and identify potential responders to treatment. Twenty-four women with CPP associated with dyspareunia were treated with 90 units of BoNT/A injected into their pelvic floor muscle (PFM). Clinical status and PFM activity were monitored in a previous visit (PV) and 12 and 24 weeks after the infiltration (W12, W24) by validated clinical questionnaires and surface electromyography (sEMG). The influence of patients’ characteristics on the reduction in pain at W12 and W24 was also assessed. After treatment, pain scores and the impact of symptoms on quality of life dropped significantly, sexual function improved and sEMG signal amplitude decreased on both sides of the PFM with no adverse events. Headaches and bilateral pelvic pain were risk factors for a smaller pain improvement at W24, while lower back pain was a protective factor. Apart from reporting a significant clinical improvement of patients with CPP associated with dyspareunia after BoNT/A infiltration, this study shows that clinical characteristics should be analyzed in detail to identify potential responders to treatment.

Sign in / Sign up

Export Citation Format

Share Document